MaxCyte and Vittoria Biotherapeutics sign strategic platform license to advance next generation cellular therapies

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, and Vittoria Biotherapeutics (Vittoria), a leading edge, gene-edited cell therapeutics company with novel platform technologies poised to develop a pipeline of highly differentiated cellular therapies for both oncology and immunology indications, today announced the signing of a strategic platform license (SPL) of MaxCyte’s Flow Electroporation® technology and ExPERT platform to Vittoria Biotherapeutics.

Under the terms of the agreement, Vittoria will obtain non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT platform. In return, MaxCyte is entitled to receive platform licensing fees and program-related revenue.

Vittoria’s technology and clinical programs are designed to address current gaps with contemporary cell therapies and the Company is planning to file an investigational new drug application (IND) for their lead program, Viper 101, later this year. Viper 101 is a gene-edited, autologous, dual-population cell therapy developed from Vittoria’s proprietary Senza5 platform that addresses significant unmet therapeutic need for the treatment of T-cell lymphoma. Vittoria’s patent-protected Senza5 platform technology is designed to improve the viability, efficacy, and safety of CAR-T treatments by modulating a novel checkpoint pathway in engineered T-cells. Senza5 CAR-T cells have demonstrated superior anti-tumor efficacy in both liquid and solid tumor preclinical models and utilize a proprietary five-day manufacturing process.

Working with partners to produce best-in-class solutions that accelerate the development of novel therapies to improve patient outcomes is central to our company’s mission. Through our partnership with Vittoria, MaxCyte has gained an opportunity to further validate and showcase our technology in a real-world setting and expand its footprint in the promising field of CAR-T therapies. We look forward to supporting Vittoria’s efforts to improve efficacy and enhance safety of T-cell therapies.”

Doug Doerfler, President and Chief Executive Officer, MaxCyte

“At Vittoria, our goal is to deliver next-generation T-cell therapies designed to improve patient outcomes by enhancing the overall clinical utility and safety of engineered cell therapies,” said Nicholas Siciliano, Ph.D., Chief Executive Officer of Vittoria. “MaxCyte's experience with clinical grade manufacturing of gene-edited cellular therapeutics will greatly enhance the robustness and reproducibility of our manufacturing process, ensuring that each batch of our CAR-T cells meets the highest standards of consistency and quality. This is an important step forward as we work to develop the next generation of cellular therapies to benefit patients.”

MaxCyte’s ExPERT™ instrument portfolio is the next generation of leading, clinically validated electroporation technology for complex and scalable cell engineering. By delivering high transfection efficiency, seamless scalability and enhanced functionality, the ExPERT platform delivers the high-end performance essential to enabling the next wave of biological and cellular therapeutics. Vittoria is MaxCyte’s 22nd SPL overall.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    MaxCyte, Inc.. (2023, August 10). MaxCyte and Vittoria Biotherapeutics sign strategic platform license to advance next generation cellular therapies. News-Medical. Retrieved on July 24, 2024 from https://www.news-medical.net/news/20230810/MaxCyte-and-Vittoria-Biotherapeutics-sign-strategic-platform-license-to-advance-next-generation-cellular-therapies.aspx.

  • MLA

    MaxCyte, Inc.. "MaxCyte and Vittoria Biotherapeutics sign strategic platform license to advance next generation cellular therapies". News-Medical. 24 July 2024. <https://www.news-medical.net/news/20230810/MaxCyte-and-Vittoria-Biotherapeutics-sign-strategic-platform-license-to-advance-next-generation-cellular-therapies.aspx>.

  • Chicago

    MaxCyte, Inc.. "MaxCyte and Vittoria Biotherapeutics sign strategic platform license to advance next generation cellular therapies". News-Medical. https://www.news-medical.net/news/20230810/MaxCyte-and-Vittoria-Biotherapeutics-sign-strategic-platform-license-to-advance-next-generation-cellular-therapies.aspx. (accessed July 24, 2024).

  • Harvard

    MaxCyte, Inc.. 2023. MaxCyte and Vittoria Biotherapeutics sign strategic platform license to advance next generation cellular therapies. News-Medical, viewed 24 July 2024, https://www.news-medical.net/news/20230810/MaxCyte-and-Vittoria-Biotherapeutics-sign-strategic-platform-license-to-advance-next-generation-cellular-therapies.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
MaxCyte joins the alliance for mRNA medicines (AMM) as a founding member